Nov 6, 2015 12:30 pm EST Lixte Biotechnology Holdings, Inc. Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity
Sep 17, 2015 1:00 pm EDT Lixte Biotechnology Holdings, Inc. Engages BioPharmaWorks LLC To Enhance Development Of Its Pipeline Of Novel Compounds
Feb 25, 2015 9:04 am EST Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies
Jan 23, 2015 9:04 am EST Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
Nov 6, 2014 10:00 am EST Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch
Jun 18, 2014 9:04 am EDT Lixte's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer
Apr 25, 2013 9:00 am EDT Lixte Biotechnology Announces Initiation Of A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
Nov 27, 2012 9:00 am EST Lixte Biotechnology Holdings Announces New Appointment To Board Of Directors
